Technology

Our solid form screening technology applies to polymorph screening, salt screening and cocrystal screening. Our screening technology is to design various crystallization conditions according to the physicochemical properties of the target compound and factors affecting drug crystallization, to screen and discover the most comprehensive solid form for subsequent evaluation and development. Our proprietary solid form screening technology has been applied to over 1,500 different drug molecules and proven to be efficient and effective in screening and identifying the most optimal solid form for development.

Solid form developability evaluation technology is to evaluate the developability of crystal forms, including polymorphs, salts and cocrystals obtained in the solid form screening experiments and analyze potential risks and challenges of development. Through years of technical accumulation, Crystal Pharmatech has formed a complete evaluation system for solid form developability.

Single crystal growth and structure determination technology are the main methods to determine the absolute configuration of drug molecules and identify the crystal forms absolutely. The single crystal culture and analysis technology firstly obtain high-quality crystals through a variety of experimental single crystal growth methods. The main single crystal growth methods include slow evaporation, gas-liquid infiltration, slow cooling and liquid surface diffusion.

On the basis of in-depth research on the properties of the crystal form itself and the transformation relationship between crystal forms, Crystal Pharmatech's crystallization process development technology realizes the selection and control of the crystallization system, crystallization conditions and post-processing conditions, so as to obtain the target crystal form at the same time taking into account the API particle properties, yield and cost, etc.

Oral solid dosage forms are an important part of the global pharmaceutical market, accounting for most of the small molecule pharmaceutical market, of which tablets and capsules are the most common dosage forms. With the vigorous development of domestic and foreign innovative drugs and the rise of global Biotech, its asset-light and R&D-focused development model will choose more outsourcing forms.

With the ever-increasing demand for the absorbability of small-molecule oral innovative drugs, more and more new molecules have hydrophobic properties, resulting in very low solubility. According to the latest statistics, about 70% of the small-molecule drugs under research are insoluble substances of BCS II or IV.

Pediatric medication is a long-standing unmet clinical need in China. Taking medicine by breaking, guessing on dosage, and lack of special medicines are the main chaos in pediatric medication. From the perspective of physiology and pharmacology, they are not just "miniature versions" of adult drugs, and corresponding changes in dosage form, dosage, and administration form are required.